Cargando…

1750. Factors associated with respiratory pathogen panel utilization in children hospitalized with acute respiratory illness — New Vaccine Surveillance Network, Kansas City, 2017–2021

BACKGROUND: Respiratory pathogen panels (RPP) are multiplex PCR platforms that detect several respiratory viruses from one specimen. For most children hospitalized with acute respiratory illness (ARI), management is supportive, and detection of a specific virus from RPP does not impact clinical care...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyon, Edward, Lee, Brian R, Clopper, Benjamin R, Moline, Heidi L, Selvarangan, Rangaraj, Schuster, Jennifer E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677241/
http://dx.doi.org/10.1093/ofid/ofad500.1581
_version_ 1785150083516334080
author Lyon, Edward
Lee, Brian R
Clopper, Benjamin R
Moline, Heidi L
Selvarangan, Rangaraj
Schuster, Jennifer E
author_facet Lyon, Edward
Lee, Brian R
Clopper, Benjamin R
Moline, Heidi L
Selvarangan, Rangaraj
Schuster, Jennifer E
author_sort Lyon, Edward
collection PubMed
description BACKGROUND: Respiratory pathogen panels (RPP) are multiplex PCR platforms that detect several respiratory viruses from one specimen. For most children hospitalized with acute respiratory illness (ARI), management is supportive, and detection of a specific virus from RPP does not impact clinical care. Therefore, clinical RPP use is not standardized, and ordering is at the discretion of the clinician. We sought to understand factors associated with RPP utilization among pediatric patients hospitalized with ARI. METHODS: From October 2017 to September 2021, participants < 18 years hospitalized with ARI were enrolled at a single site in the New Vaccine Surveillance Network (NVSN). Eligible patients were residents of Jackson County, MO, had one or more ARI symptoms (e.g., cough, fever, nasal congestion) lasting < 14 days, and were enrolled within 48 hours of admission. Parent interviews and medical chart reviews were conducted. All participants had a research RPP, but results were not available to the clinical providers. Clinical providers were able to order a clinical RPP (cRPP), for which they received test results. Characteristics of NVSN enrollees hospitalized with ARI with and without a cRPP are described. Lastly, medical complexity was assessed via the pediatric complex chronic conditions classification system (CCC) then analyzed via chi- square test between groups. RESULTS: During the study period, 1,038 participants were enrolled, and 555 (53.4%) received a cRPP. Most, 299 (53%), cRPPs were ordered in the emergency department or urgent care before admission. Age was a significant factor associated with cRPP use (Table 1). cRPP participants were more likely to have complex chronic conditions, and/or technology dependence. No difference in cRPP use was observed by race/ethnicity, payer status, or sex. More participants were enrolled in 2020-2021, but the overall usage of cRPP is similar between years (Table 2). [Figure: see text] [Figure: see text] CONCLUSION: In this large cohort of children hospitalized with ARI, medical complexity, technological dependence, and age < 2 months were associated with increased utilization of cRPPs. Understanding the impact of cRPP on clinical care requires further investigation to better understand the utility of these tests. DISCLOSURES: Rangaraj Selvarangan, BVSc, PhD, D(ABMM), FIDSA, FAAM, Abbott: Honoraria|Altona Diagnostics: Grant/Research Support|Baebies Inc: Advisor/Consultant|BioMerieux: Advisor/Consultant|BioMerieux: Grant/Research Support|Bio-Rad: Grant/Research Support|Cepheid: Grant/Research Support|GSK: Advisor/Consultant|Hologic: Grant/Research Support|Lab Simply: Advisor/Consultant|Luminex: Grant/Research Support
format Online
Article
Text
id pubmed-10677241
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106772412023-11-27 1750. Factors associated with respiratory pathogen panel utilization in children hospitalized with acute respiratory illness — New Vaccine Surveillance Network, Kansas City, 2017–2021 Lyon, Edward Lee, Brian R Clopper, Benjamin R Moline, Heidi L Selvarangan, Rangaraj Schuster, Jennifer E Open Forum Infect Dis Abstract BACKGROUND: Respiratory pathogen panels (RPP) are multiplex PCR platforms that detect several respiratory viruses from one specimen. For most children hospitalized with acute respiratory illness (ARI), management is supportive, and detection of a specific virus from RPP does not impact clinical care. Therefore, clinical RPP use is not standardized, and ordering is at the discretion of the clinician. We sought to understand factors associated with RPP utilization among pediatric patients hospitalized with ARI. METHODS: From October 2017 to September 2021, participants < 18 years hospitalized with ARI were enrolled at a single site in the New Vaccine Surveillance Network (NVSN). Eligible patients were residents of Jackson County, MO, had one or more ARI symptoms (e.g., cough, fever, nasal congestion) lasting < 14 days, and were enrolled within 48 hours of admission. Parent interviews and medical chart reviews were conducted. All participants had a research RPP, but results were not available to the clinical providers. Clinical providers were able to order a clinical RPP (cRPP), for which they received test results. Characteristics of NVSN enrollees hospitalized with ARI with and without a cRPP are described. Lastly, medical complexity was assessed via the pediatric complex chronic conditions classification system (CCC) then analyzed via chi- square test between groups. RESULTS: During the study period, 1,038 participants were enrolled, and 555 (53.4%) received a cRPP. Most, 299 (53%), cRPPs were ordered in the emergency department or urgent care before admission. Age was a significant factor associated with cRPP use (Table 1). cRPP participants were more likely to have complex chronic conditions, and/or technology dependence. No difference in cRPP use was observed by race/ethnicity, payer status, or sex. More participants were enrolled in 2020-2021, but the overall usage of cRPP is similar between years (Table 2). [Figure: see text] [Figure: see text] CONCLUSION: In this large cohort of children hospitalized with ARI, medical complexity, technological dependence, and age < 2 months were associated with increased utilization of cRPPs. Understanding the impact of cRPP on clinical care requires further investigation to better understand the utility of these tests. DISCLOSURES: Rangaraj Selvarangan, BVSc, PhD, D(ABMM), FIDSA, FAAM, Abbott: Honoraria|Altona Diagnostics: Grant/Research Support|Baebies Inc: Advisor/Consultant|BioMerieux: Advisor/Consultant|BioMerieux: Grant/Research Support|Bio-Rad: Grant/Research Support|Cepheid: Grant/Research Support|GSK: Advisor/Consultant|Hologic: Grant/Research Support|Lab Simply: Advisor/Consultant|Luminex: Grant/Research Support Oxford University Press 2023-11-27 /pmc/articles/PMC10677241/ http://dx.doi.org/10.1093/ofid/ofad500.1581 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Lyon, Edward
Lee, Brian R
Clopper, Benjamin R
Moline, Heidi L
Selvarangan, Rangaraj
Schuster, Jennifer E
1750. Factors associated with respiratory pathogen panel utilization in children hospitalized with acute respiratory illness — New Vaccine Surveillance Network, Kansas City, 2017–2021
title 1750. Factors associated with respiratory pathogen panel utilization in children hospitalized with acute respiratory illness — New Vaccine Surveillance Network, Kansas City, 2017–2021
title_full 1750. Factors associated with respiratory pathogen panel utilization in children hospitalized with acute respiratory illness — New Vaccine Surveillance Network, Kansas City, 2017–2021
title_fullStr 1750. Factors associated with respiratory pathogen panel utilization in children hospitalized with acute respiratory illness — New Vaccine Surveillance Network, Kansas City, 2017–2021
title_full_unstemmed 1750. Factors associated with respiratory pathogen panel utilization in children hospitalized with acute respiratory illness — New Vaccine Surveillance Network, Kansas City, 2017–2021
title_short 1750. Factors associated with respiratory pathogen panel utilization in children hospitalized with acute respiratory illness — New Vaccine Surveillance Network, Kansas City, 2017–2021
title_sort 1750. factors associated with respiratory pathogen panel utilization in children hospitalized with acute respiratory illness — new vaccine surveillance network, kansas city, 2017–2021
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677241/
http://dx.doi.org/10.1093/ofid/ofad500.1581
work_keys_str_mv AT lyonedward 1750factorsassociatedwithrespiratorypathogenpanelutilizationinchildrenhospitalizedwithacuterespiratoryillnessnewvaccinesurveillancenetworkkansascity20172021
AT leebrianr 1750factorsassociatedwithrespiratorypathogenpanelutilizationinchildrenhospitalizedwithacuterespiratoryillnessnewvaccinesurveillancenetworkkansascity20172021
AT clopperbenjaminr 1750factorsassociatedwithrespiratorypathogenpanelutilizationinchildrenhospitalizedwithacuterespiratoryillnessnewvaccinesurveillancenetworkkansascity20172021
AT molineheidil 1750factorsassociatedwithrespiratorypathogenpanelutilizationinchildrenhospitalizedwithacuterespiratoryillnessnewvaccinesurveillancenetworkkansascity20172021
AT selvaranganrangaraj 1750factorsassociatedwithrespiratorypathogenpanelutilizationinchildrenhospitalizedwithacuterespiratoryillnessnewvaccinesurveillancenetworkkansascity20172021
AT schusterjennifere 1750factorsassociatedwithrespiratorypathogenpanelutilizationinchildrenhospitalizedwithacuterespiratoryillnessnewvaccinesurveillancenetworkkansascity20172021